Zenas BioPharma (NASDAQ:ZBIO) Given Outperform Rating at Wedbush

Wedbush reiterated their outperform rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a research report report published on Friday,Benzinga reports. The firm currently has a $45.00 price target on the stock.

Several other research analysts have also issued reports on the stock. Wall Street Zen raised shares of Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Zacks Research upgraded shares of Zenas BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings cut shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Finally, Morgan Stanley boosted their target price on Zenas BioPharma from $21.00 to $22.00 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $45.71.

Zenas BioPharma Trading Up 1.1%

Shares of ZBIO stock opened at $29.51 on Friday. The company has a market cap of $1.86 billion, a P/E ratio of -3.28 and a beta of -1.03. The stock has a 50 day simple moving average of $26.95 and a two-hundred day simple moving average of $23.38. The company has a debt-to-equity ratio of 1.04, a quick ratio of 11.94 and a current ratio of 11.94. Zenas BioPharma has a fifty-two week low of $13.50 and a fifty-two week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $15.00 million. Research analysts forecast that Zenas BioPharma will post -4.47 earnings per share for the current year.

Insider Buying and Selling

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 60,000 shares of the stock in a transaction on Monday, May 18th. The shares were purchased at an average price of $16.88 per share, for a total transaction of $1,012,800.00. Following the completion of the acquisition, the chief executive officer owned 96,928 shares in the company, valued at approximately $1,636,144.64. This represents a 162.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jupiter Topco LLC bought a new position in Zenas BioPharma in the 2nd quarter valued at about $201,000. J. Goldman & Co LP bought a new stake in Zenas BioPharma during the 2nd quarter worth approximately $1,732,000. Legal & General Group Plc bought a new stake in Zenas BioPharma during the 2nd quarter worth approximately $508,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Zenas BioPharma in the second quarter worth approximately $204,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Zenas BioPharma in the second quarter worth approximately $49,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.